Globalpharma, a subsidiary of Dubai Investments Industries, the industry arm of Dubai Investments has announced that it has recently received regulatory approval from the Medicines Control Council (MCC) of South Africa.

This approval has confirmed Globalpharma’s position as the first pharmaceutical manufacturing company in Dubai that adheres to international quality standards, said a company official.

"The MCC approval will allow Globalpharma to market its penicillin products across South Africa as well as manufacture penicillin products for South African pharmaceutical companies in its premises in Dubai," Jamil Akhtar, Globalpharma general manager, pointed out.

Globalpharma also plans to launch new products in South Africa in the coming years beginning with a range of Amoxicillin and Amoxicillin-Clavulanic acid combination under the brand names Glomox and Gloclav.

Gloclav 375 mg and 625 mg tablets are currently pending registration in South Africa.

Glomox and Gloclav are antibiotics commonly used in different infective conditions like tonsillitis, otitis media (ear infections), sinusitis (sinus infections), bronchitis (respiratory infections) urinary tract infections and dental infection (after tooth extraction).

“The MCC is a health authority that follows very stringent standards of inspection and we, at Globalpharma, are thrilled to have received the ‘Good Manufacturing Practice’ (GMP) certification from it,” Akhtar observed.

“The certification comes as an irrefutable piece of proof of the world-class quality standards we maintain and we believe that it is a big milestone in our journey towards other approvals from prominent international authorities such as the Medicines and Healthcare products Regulatory Agency, UK and the Food and Drug Administration (FDA), USA,” he added.

Established in 1998, Globalpharma manufactures and markets its own pharmaceutical products including antibiotics, cardiovascular, anti-ulcerants, analgesic NSAIDs, food supplements, vitamins, anti-diabetics, respiratory products in more than 20 countries in addition to marketing in license products from some other multinational pharmaceutical companies.-TradeArabia News Service